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Objective: Autism spectrum disorders (ASDs) are highly heritable neurodevelopmental
disorders that onset clinically during the first years of life. ASD risk biomarkers expressed
early in life could significantly impact diagnosis and treatment, but no transcriptome-wide
biomarker classifiers derived from fresh blood samples from children with autism have yet
emerged. Method: Using a community-based, prospective, longitudinal method, we iden-
tified 60 infants and toddlers at risk for ASDs (autistic disorder and pervasive developmental
disorder), 34 at-risk for language delay, 17 at-risk for global developmental delay, and 68
typically developing comparison children. Diagnoses were confirmed via longitudinal follow-
up. Each child’s mRNA expression profile in peripheral blood mononuclear cells was
determined by microarray. Results: Potential ASD biomarkers were discovered in one-half
of the sample and used to build a classifier, with high diagnostic accuracy in the remaining half
of the sample. Conclusions: The mRNA expression abnormalities reliably observed in
peripheral blood mononuclear cells, which are safely and easily assayed in infants, offer the
first potential peripheral blood–based, early biomarker panel of risk for autism in infants and
toddlers. Future work should verify these biomarkers and evaluate whether they may also
serve as indirect indices of deviant molecular neural mechanisms in autism. J. Am. Acad. Child
Adolesc. Psychiatry, 2012;51(9):934–944. Key Words: autism, biomarker, classifier, microar-
ray, support vector machinel
A utism spectrum disorders (ASDs), suchas autistic disorder (AD) and pervasivedevelopmental disorder not otherwise
specified (PDD), are among the most prevalent
neurodevelopmental disorders, collectively af-
fecting almost 1% of the U.S. population.1 These
are also among the most severe and debilitating
disorders of early brain development, typically
emerging between infancy and early childhood,
and commonly imposing lifelong disability on
affected children as well as considerable strain on
their caretakers and society at large. One way to
combat ASDs would be to discover biological
signatures—or “biomarkers”—of early risk for
ASDs that could be exploited for early detection
and treatment and could thereby improve long-
term clinical outcomes.2Supplemental material cited in this article is available online.
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expression in ASDs have used post mortem brain
tissue3,4 or transformed lymphoblastoid cell
ines.5-8 Both approaches are quite useful and
revealing, often observing dysregulation of vi-
able candidate pathways in autism, but both
have limitations, such as the inability to fully
account for agonal factors or the effects of viral
transformation on the observed gene expres-
sion differences in autism. In contrast, Kuwano
et al.9 sought autism biomarkers in peripheral
leukocytes of young adults with autism, ob-
serving dysregulation of 16 genes related to cell
morphology, cellular assembly and organiza-
tion, and nerve system development and func-
tion. Albeit informative regarding persistent
gene expression abnormalities in peripheral
blood in individuals with ASDs (and perhaps
reflecting the central nervous system pathology
accompanying the disorder), this study cannot
shed light on the peripheral blood transcriptomic
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BLOOD-BASED AUTISM BIOMARKERSevents accompanying the emergence of autism in
its earliest developmental stages of infancy or
toddlerhood.
Here we report the cross-sectional results of
whole-transcriptome expression profiling in freshly
drawn peripheral blood mononuclear cells (PBMCs)
from Wave I of data collection in a longitudinal
study of very young children (12 through 46
months of age) with or at risk for a variety of
neurodevelopmental disorders including ASDs,
language delay (LD), or global developmental de-
lay (DD), as well as children consistently judged
to be typically developing (TD) and children
initially judged as potentially at risk but, upon
further evaluation, found to be developing
typically (type I errors [TIEs]). Our analyses
were designed to reveal in peripheral blood a
biomarker signature for ASDs that might also
reveal important biological differences be-
tween TD children, children with delays not on
the autism spectrum, and children at risk for or
having an ASD.
METHOD
Subjects
Protections. The Institutional Review Boards of the
University of California, San Diego and State Univer-
sity of New York (SUNY) Upstate Medical University
approved all procedures. After referral, all minor sub-
jects assented to the study procedures, and one or both
parents or legal guardians of each subject provided
written informed consent for their child to participate.
Ascertainment. Participants were obtained via a gen-
eral population-based screening method called the
One-Year Well-Baby Check-Up Approach, which en-
gages community pediatricians to screen for autism
using the Communication and Symbolic Behavior
Scales Developmental Profile (CSBS DP) Infant–
Toddler questionnaire10,11 during regular checkups.12
More than 135 pediatricians in San Diego County
agreed to screen all consecutive infants and toddlers
seen for routine visits. All subjects failing the CSBS DP
at their pediatrician’s office were provisionally identi-
fied as at risk for one of the disorders of interest and
then referred to our Center for further evaluation.
Subjects who passed the CSBS were identified as TD,
and pediatricians randomly referred such subjects to
our Center for further evaluation as unaffected com-
parison subjects. Using this approach, toddlers as
young as 12 months were recruited and tracked every
6 months until at least their third birthday, thus
allowing the prospective study of autism beginning at
12 months.
Diagnoses. ASDs were initially diagnosed based on
the clinical judgment of a Ph.D.-level psychologist
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the three initial modules of the Autism Diagnostic
Observation Schedule (ADOS)13 and the revised algo-
rithms described by Gotham et al.14 Although several
SD subjects were only 1 year old at the time of first
lood sampling, all but one have been tracked and
iagnosed with an ASD using the toddler module of
he ADOS15 at age 2 years or beyond, when the
iagnosis of autism can be made reliably. Final diag-
oses for participants with an ASD older than 30
onths (including some of the youngest subjects who
ad previously been diagnosed with or at-risk for an
SD based on the ADOS) were confirmed with the
utism Diagnostic Interview–Revised (ADI-R).15
Subjects who failed the CSBS DP Infant–Toddler ques-
tionnaire but who passed the ADOS were diagnosed
with LD if one or both of the language subtest scores of
the Mullen Scales of Early Learning were more than
one standard deviation lower than expected for that
age (T score 40). Because a significant percentage of
individuals with ASDs exhibit language deficits not
restricted to the pragmatic component of lan-
guage,16-19 this approach to diagnosing LD may not
be highly specific; however, this criterion paired
with ADOS evaluations not consistent with an ASD
is sufficient to establish that these subjects have
some language delay and are not on the autistic
spectrum, making them suitable as an affected,
nonautistic comparison sample for establishing the
specificity of our ASD biomarkers. Subjects who
failed the CSBS DP Infant–Toddler questionnaire but
who passed the ADOS were diagnosed with global
DD if scores were more than one standard deviation
lower than expected on three or more subtests of the
Mullen Scales and the overall developmental quo-
tient was more than one standard deviation lower
than expected (85). Subjects who failed the CSBS
DP Infant–Toddler questionnaire but who passed
the ADOS and who did not deviate from norms on
any of the Mullen Scales or the developmental
quotient were judged to be developing typically and
identified as TIEs.
Laboratory Methods
From each subject, 4 ml of venous blood was collected
into EDTA-coated collection tubes and immediately
transferred to an RNase-free laboratory where all
subsequent procedures took place, including RNA
isolation and storage at 80°C within 6 hours. Meth-
ods of mRNA extraction, stabilization, isolation, stor-
age, quantitation, reverse transcription, and microar-
ray hybridization, as well as methods of microarray
scanning and data import, normalization, and trans-
formation, were consistent with our prior work20 (see
Supplemental Method, available online).
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GLATT et al.Quality Control and Final Sample Constitution
The quality of mRNA samples was quantified by the
RNA Integrity Number (RIN) and, according to con-
vention,21 values of 6.0 or greater were deemed accept-
able; values observed in our sample ranged from 9.0 to
10.0. A total of 339 samples selected for analysis in
Wave I had acceptable levels of mRNA quantity,
purity, and quality. Once microarray data were gener-
ated, the first three principal components of global
gene expression patterns in each individual were vi-
sualized. Subjects whose values on each of these three
principal components were beyond four standard de-
viations from the grand mean (n  5) were removed
from further analyses, as this type of deviation indi-
cates that typical patterns of global gene coexpression
and correlation have been disrupted (by either a bio-
logical process or, more likely in our experience, a
laboratory technical problem). Eighteen additional
subjects were removed because of low signal intensity,
as observed by box-plot and evidenced by an average
signal more than two standard deviations below the
mean, which likely indicates generally low hybridiza-
tion efficiency and unreliability of the data from those
arrays. Of the remaining 316 quality-assured samples,
179 were first-timepoint samples from a child proband
in one of the six diagnostic groups described in Table
1. The remaining 137 samples were from parents or
siblings of probands, or from probands evaluated at a
second timepoint, and so were not formally analyzed
for the present report. There was no significant over-
all sex difference between the six diagnostic groups
TABLE 1 Demographic and Clinical Characteristics of th
AD PDD
Sample size, n 37 23
Sex, male:female 29:8 20:3
Age, mo, range 13–46 12–41
Mean (SD) 26.9 (9.2) 28.7 (8
Mullen Early Learning Composite
Score, mean (SD)
69.2 (19.8)b 77.4 (1
Vineland Adaptive Behavior Scales
Standard Score, mean (SD)
79.9 (12.2)c 82.6 (9
ADOS-T Social Affect Score,
mean (SD)
14.8 (4.9)d 10.7 (3
ADOS-T Restricted/Repetitive
Score, mean (SD)
3.1 (1.6)e 2.2 (1
ADOS-T Total Score, mean (SD) 17.9 (5.8)f 13.0 (3
Note: aAge: significantly different (p .05) from autistic disorder (AD), dev
(PDD), and typically developing (TD) groups.
bMullen: significantly different (p  .05) from TD and type I error (TIE) gro
cVineland: significantly different (p  .05) from language delay (LD), TD,
dAutism Diagnostic Observation Schedule–Toddler (ADOS-T) Social Affect: sig
eADOS-T Restricted/Repetitive: significantly different (p  .05) from all ot
fADOS-T Total: significantly different (p  .05) from all other diagnostic groups,
JOURN
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age (F[5,173]  13.77, p  .0001), reflecting that the LD
nd TIE groups were significantly younger than the
D, DD, PDD, and TD groups (Scheffe test, all p 
.05). This age difference should be put into context
however, as the full age range for our entire sample is
only 34 months, which is still relatively narrow for a
study of early autism; nevertheless, all subsequent
statistical analyses accounted for age as a covariate. As
expected, AD and PDD groups differed significantly
from both the TD and the TIE control groups on all
clinical scale scores, including the Mullen Early Learn-
ing Composite Score, Vineland Adaptive Behavior
Scales Standard Score, Autism Diagnostic Observa-
tion Schedule–Toddler (ADOS-T) Social Affect Score,
ADOS-T Restricted/Repetitive Score, and ADOS-T To-
tal Score. The AD and PDD groups also differed from
each other on the ADOS-T Social Affect and Total
Scores, with the AD group showing overall greater
symptom severity. The majority of subjects in the
full sample and within each diagnostic group was of
white ancestry, with no other ancestral group
(Asian, Pacific Islander, African American, Ameri-
can Indian, or Mixed) individually comprising more
than 10% of any diagnostic group, and there were no
differences in overall ancestral composition bet-
ween any of the diagnostic groups (Pearson 2(25) 
1.516; p  .664). To increase sample size and
nferential power, and maintain consistency with the
onceptualization of AD and PDD as disorders on
he same spectrum, we pooled these samples to-
Diagnostic Groups
Diagnostic Group
DD LD TD TIE
17 34 27 41
13:4 26:8 14:13 26:15
13–43 12–32 12–45 13–38
25.0 (8.5) 17.4 (4.6)a 22.0 (9.0) 16.8 (5.8)a
63.6 (12.6) 94.3 (12.8) 116.6 (13.3) 105.4 (14.0)
76.8 (15.2) 93.8 (7.7) 105.5 (9.7) 101.9 (9.5)
6.8 (4.7) 4.0 (3.5) 1.8 (1.5) 2.5 (1.8)
1.4 (1.6) 0.9 (1.0) 0.6 (1.1) 0.5 (1.4)
8.2 (5.4) 4.9 (3.8) 2.3 (1.8) 3.0 (2.5)
ental delay (DD), pervasive developmental disorder not otherwise specified
IE groups.
tly different (p  .05) from all other diagnostic groups, including each other.
agnostic groups, but not each other.e Six
.1)
4.8)b
.8)c
.2)d
.5)e
.2)f
elopm
ups.
and T
nifican
her diincluding each other.
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BLOOD-BASED AUTISM BIOMARKERSgether into one ASD group for all subsequent anal-
yses; likewise, we pooled both typically developing
groups (TD and TIE) into one unaffected control
(CNT) group for all subsequent analyses, acknowl-
edging that other interesting combinations and com-
parisons could be tested.
Microarray Data Analyses
The ASD sample was split into two independent
subgroups: a discovery sample and a replication sam-
ple. The two subsamples were drawn to be equivalent
in sample size, age, sex, and diagnostic composition
(AD versus PDD). The CNT sample was similarly split
into discovery and replication samples drawn to be
equivalent in size, age, sex, and diagnostic composi-
tion (TD versus TIE). The basic analytic model for
identifying candidate biomarkers in the discovery
samples was an analysis of covariance (ANCOVA),
with each gene’s expression intensity value as the
dependent measure, diagnostic group (ASD versus
CNT) and sex as fixed between-subjects factors, and
age in months as a continuous covariate. Genes with
expression levels influenced by at least a nominally
significant main effect of diagnostic group (p  .05)
and with log2 fold change in the ASD group of |1.2|
were identified as putative candidate ASD biomarkers
and advanced to the next phase of analysis. These
fairly liberal criteria were used to cast a wide net to
catch all potentially informative genes, whereas false
positive results would be pared off the putative bio-
marker set by subsequent model building, optimiza-
tion, and replication steps. These genes were then used
to build a support vector machine (SVM) classifier of
the same discovery sample in which they were initially
discovered. The SVM was configured as cost-based,
with costs varied from 1 to 1001 in intervals of 100. The
tolerance (termination criterion) of the SVM was set at
0.001. The kernel for the SVM was a radial basis
function, with gamma equal to the inverse of the
number of evaluated markers. The optimal (i.e., the
most accurate and parsimonious) SVM was derived by
shrinking centroids (which prunes highly correlated or
redundant features) and 10-fold cross-validation. The
optimal SVM classifier was then tested for classifica-
tion accuracy in the fully independent ASD and CNT
replication samples, and then re-evaluated in the pres-
ence of the LD and DD samples as affected but
nonautistic comparators. The list of genes comprising
the optimal classifier was subjected to the Database for
Annotation, Visualization, and Integrated Discovery
(DAVID)22 algorithm to determine whether it was
enriched with genes having particular functional, on-
tological, or structural annotations. Fold enrichments
of such annotations were declared statistically signifi-
cant only if they surpassed a Bonferroni-corrected
p value threshold of   0.05/number of terms eval-
uated in a particular category.
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Discovery Samples
Putative Biomarker Identification by ANCOVA. We
found 2,540 probes with expression levels that
were at least nominally significantly different
(0.05p3.0e6) between the ASD and CNT
groups. When limiting this probe set to only those
that showed significant dysregulation in ASD (p 
.05) and a log2 fold change  |1.2|, 154 probes
remained (Table 2). The log2 fold change in these
probes ranged from 2.1-fold up-regulation to 1.7-fold
down-regulation, corresponding to actual changes of
4.3-fold up-regulation and 3.2-fold down-regulation,
respectively.
Construction of Optimal SVM Classifier. The 154
probes meeting our significance and fold change
criteria were used to construct, optimize, and test
the classification accuracy of various SVMs. The
most accurate SVM (cost 901, gamma 0.001) used
the expression intensities of 48 probes (Table 2) to
correctly classify 71% of ASD and CNT subjects
across 10 subsets of the discovery sample into their
appropriate diagnostic categories. In all, 22 of 30
ASD subjects were correctly classified by this SVM
as having an ASD, whereas 23 of 34 CNT subjects
were correctly classified as CNT subjects. The cor-
responding sensitivity and specificity of this SVM
after 10-fold cross-validation were 0.73 and 0.68,
respectively.
Replication Samples
Evaluation of Optimal SVM Classifier. The identi-
cal 48-probe SVM classifier optimized in the
discovery sample performed almost perfectly in
the replication sample, with an accuracy of 91%.
Two of 30 ASD subjects were incorrectly identi-
fied as CNT subjects, and four of 34 CNT subjects
were misclassified as ASD subjects. The corre-
sponding sensitivity and specificity of this SVM
were 0.93 and 0.88, respectively. The area under
the receiver operating characteristic (ROC) curve
generated from these classifications was 0.91.
When the optimized 48-probe SVM diagnostic
classifier of ASDs was deployed to classify the
ASD and CNT replication samples in the pres-
ence of LD and DD samples, its accuracy was
only slightly attenuated to 87%. Two of 30 ASD
subjects in the replication sample were misclas-
sified (one as CNT and one as LD), and eight of
36 individuals classified by the SVM as ASD
group members were not actually diagnosed as
such (including four CNT subjects, one DD sub-
ject, and three LD subjects). Although it was not
937www.jaacap.org
GLATT et al.TABLE 2 Probes Significantly Dysregulated (p  .05, Fold Change|1.2|) in the Autism Spectrum Disorder (ASD)
Discovery Sample Compared With the Unaffected Control Group (CNT) Discovery Sample
Probe IDa Gene Symbol Gene Product
Log2 Fold
Changeb p
ILMN_2261600 FCGR1A Fc fragment of IgG, high affinity Ia, receptor (CD64) 1.69 1.29E-02
ILMN_1799848 ANKRD22 Ankyrin repeat domain 22 1.65 2.63E-02
ILMN_2114568 GBP5 Guanylate binding protein 5 1.65 3.89E-03
ILMN_2132599 ANKRD22 Ankyrin repeat domain 22 1.64 2.77E-02
ILMN_1743145 L-RAP Homo sapiens l-rap mRNA for leukocyte-derived arginine
aminopeptidase long form variant, complete cds.
1.62 3.91E-02
ILMN_2391051 FCGR1B Fc fragment of IgG, high affinity Ib, receptor (CD64) 1.62 8.29E-03
ILMN_2148785 GBP1 Guanylate binding protein 1, interferon-inducible, 67kDa 1.60 1.04E-02
ILMN_2176063 FCGR1A Fc fragment of IgG, high affinity Ia, receptor (CD64) 1.59 2.31E-02
ILMN_1687306 LGALS2 Lectin, galactoside-binding, soluble, 2 1.52 6.16E-03
ILMN_1694548 ANXA3 Annexin A3 1.51 2.80E-03
ILMN_1786303 LILRA3 Leukocyte immunoglobulin-like receptor, subfamily A (without
TM domain), member 3
1.51 3.83E-02
ILMN_1701114 GBP1 Guanylate binding protein 1, interferon-inducible, 67kDa 1.49 4.02E-02
ILMN_1708934 ADM Adrenomedullin 1.47 5.90E-03
ILMN_1745242 PLSCR1 Phospholipid scramblase 1 1.47 3.18E-02
ILMN_1753111 NAMPT Nicotinamide phosphoribosyltransferase 1.46 4.22E-02
ILMN_1666078 HLA-H Major histocompatibility complex, class I, H (pseudogene) 1.41 2.66E-02
ILMN_1720771 STX11 Syntaxin 11 1.41 2.77E-03
ILMN_1782487 GBP1 Guanylate binding protein 1, interferon-inducible, 67kDa 1.40 3.14E-02
ILMN_1795336 PTER Phosphotriesterase related 1.40 1.33E-03
ILMN_1689734 IL1RN Interleukin 1 receptor antagonist 1.40 4.15E-02
ILMN_1771385 BC050625 Hs.409925 1.39 2.35E-02
ILMN_2050911 SLC22A4 Solute carrier family 22 (organic cation/ergothioneine
transporter), member 4
1.39 4.21E-03
ILMN_1700067 BTN3A2 Butyrophilin, subfamily 3, member A2 1.39 1.11E-02
ILMN_1748915 S100A12 S100 calcium binding protein A12 1.38 2.58E-02
ILMN_1755843 SLC26A8 Solute carrier family 26, member 8 1.37 7.40E-03
ILMN_1756806 DQ893795 Hs.719112 1.35 1.92E-02
ILMN_1653871 NAMPT Nicotinamide phosphoribosyltransferase 1.35 1.85E-02
ILMN_1652003 GNG10 Guanine nucleotide binding protein (G protein), gamma 10 1.35 4.91E-03
ILMN_1757074 GNG10 Guanine nucleotide binding protein (G protein), gamma 10 1.35 9.47E-03
ILMN_1721116 USP10 Ubiquitin specific peptidase 10 1.34 3.20E-03
ILMN_1731224 PARP9 Poly (ADP-ribose) polymerase family, member 9 1.34 2.60E-02
ILMN_1679826 CST7 Cystatin F (leukocystatin) 1.33 3.12E-02
ILMN_2335813 GCH1 GTP cyclohydrolase 1 1.33 3.73E-02
ILMN_1676528 BTN3A2 Butyrophilin, subfamily 3, member A2 1.33 3.01E-02
ILMN_1707979 CARD17 Caspase recruitment domain family, member 17 1.33 3.26E-02
ILMN_1851599 BX110640 Unknown 1.33 1.83E-02
ILMN_1696419 STOM Stomatin 1.33 2.07E-02
ILMN_2224486 C3orf14 Chromosome 3 open reading frame 14 1.33 2.65E-03
ILMN_2053527 PARP9 Poly (ADP-ribose) polymerase family, member 9 1.32 3.68E-02
ILMN_2357419 LILRA5 Leukocyte immunoglobulin-like receptor, subfamily A (with
TM domain), member 5
1.31 1.92E-02
ILMN_2294762 AMY1A Amylase, alpha 1A (salivary) 1.31 8.77E-03
ILMN_1685057 SLC22A4 Solute carrier family 22 (organic cation/ergothioneine
transporter), member 4
1.31 9.80E-03
ILMN_2256050 SERPINA1 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase,
antitrypsin), member 1
1.31 3.21E-02
ILMN_1709233 F5 Coagulation factor V (proaccelerin, labile factor) 1.31 8.64E-04
ILMN_2126706 LMNB1 Lamin B1 1.31 5.47E-03
ILMN_1810289 MYOF Myoferlin 1.30 4.60E-02
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Probe IDa Gene Symbol Gene Product
Log2 Fold
Changeb p
ILMN_1668865 SLC2A14 Solute carrier family 2 (facilitated glucose transporter),
member 14
1.30 3.54E-04
ILMN_1666742 C9orf72 Chromosome 9 open reading frame 72 1.30 1.99E-02
ILMN_1767809 GNG10 Guanine nucleotide binding protein (G protein), gamma 10 1.29 4.62E-03
ILMN_1726545 LILRA5 Leukocyte immunoglobulin-like receptor, subfamily A (with
TM domain), member 5
1.29 2.12E-02
ILMN_1684585 ACSL1 Acyl-CoA synthetase long-chain family member 1 1.29 1.28E-02
ILMN_2393296 DQ894773 Hs.1466 1.28 4.47E-02
ILMN_1725471 DQ894773 Hs.1466 1.28 3.62E-02
ILMN_2109197 EPB41L3 Erythrocyte membrane protein band 4.1-like 3 1.27 3.26E-02
ILMN_1726591 CARD16 Caspase recruitment domain family, member 16 1.27 4.53E-02
ILMN_2219712 HMGB2 High-mobility group box 2 1.26 1.55E-02
ILMN_1806015 SLC2A3 Solute carrier family 2 (facilitated glucose transporter),
member 3
1.26 5.79E-04
ILMN_1659047 HIST2H2AA4 Histone cluster 2, H2aa4 1.26 3.13E-02
ILMN_1798270 C11orf75 Chromosome 11 open reading frame 75 1.26 3.07E-02
ILMN_2232478 APOBEC3G Apolipoprotein B mRNA editing enzyme, catalytic
polypeptide-like 3G
1.26 2.62E-02
ILMN_1741727 QPCT Glutaminyl-peptide cyclotransferase 1.26 8.82E-03
ILMN_1772036 STEAP4 STEAP family member 4 1.26 3.66E-02
ILMN_1710937 IFI16 Interferon, gamma-inducible protein 16 1.25 3.15E-02
ILMN_1845037 TRIM69 Tripartite motif-containing 69 1.25 3.98E-02
ILMN_1741881 C9orf72 Chromosome 9 open reading frame 72 1.25 6.62E-03
ILMN_1795715 DPYD Dihydropyrimidine dehydrogenase 1.25 1.24E-02
ILMN_1737964 HIATL1 Hippocampus abundant transcript-like 1 1.25 1.30E-02
ILMN_1680109 COL4A3BP Collagen, type IV, alpha 3 (Goodpasture antigen) binding
protein
1.25 3.03E-02
ILMN_2412172 APOBEC3F Apolipoprotein B mRNA editing enzyme, catalytic
polypeptide-like 3F
1.25 2.16E-02
ILMN_1780546 OSM Oncostatin M 1.25 1.63E-02
ILMN_1779486 FAM126B Family with sequence similarity 126, member B 1.25 3.36E-02
ILMN_1674574 VNN1 Vanin 1 1.24 3.86E-02
ILMN_2186061 IPFK-2 Homo sapiens inducible 6-phosphofructo-2-kinase/fructose
2,6-bisphosphatase (IPFK-2) mRNA, complete cds.
1.23 1.66E-02
ILMN_1672124 C4orf18 Chromosome 4 open reading frame 18 1.23 1.91E-02
ILMN_1788002 MAPK14 Mitogen-activated protein kinase 14 1.23 6.14E-03
ILMN_1652680 NCF1B Hs.647047 1.23 4.82E-02
ILMN_1705663 DMXL2 Dmx-like 2 1.23 4.59E-02
ILMN_1804735 CBS Cystathionine-beta-synthase 1.22 4.38E-02
ILMN_1674789 Unknown Unknown 1.22 4.52E-02
ILMN_1701914 CD274 CD274 molecule 1.22 3.25E-02
ILMN_1713058 PSTPIP2 Proline-serine-threonine phosphatase interacting protein 2 1.22 3.08E-02
ILMN_2061318 TAF13 TAF13 RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 18kDa
1.22 2.48E-02
ILMN_1683250 LOC440731 Similar to hCG1817424 1.22 4.22E-02
ILMN_1659255 RP2 Retinitis pigmentosa 2 (X-linked recessive) 1.22 4.25E-02
ILMN_2061327 TAF13 TAF13 RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 18kDa
1.22 1.90E-02
ILMN_1751079 TAP1 Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) 1.22 2.42E-02
ILMN_1687201 APOL6 Apolipoprotein L, 6 1.22 4.05E-02
ILMN_1667711 DQ895783 Unknown 1.22 4.45E-02
ILMN_1801767 ABHD3 Abhydrolase domain containing 3 1.22 3.78E-02
ILMN_1776649 LRRK2 Leucine-rich repeat kinase 2 1.22 4.93E-02
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Probe IDa Gene Symbol Gene Product
Log2 Fold
Changeb p
ILMN_1781700 IL18R1 Interleukin 18 receptor 1 1.21 1.31E-02
ILMN_2078264 C3orf38 Chromosome 3 open reading frame 38 1.21 3.14E-02
ILMN_1654268 HMGB2 High-mobility group box 2 1.21 1.93E-02
ILMN_2319077 FAS Fas (TNF receptor superfamily, member 6) 1.21 3.08E-02
ILMN_1761941 C4orf18 Chromosome 4 open reading frame 18 1.21 2.23E-02
ILMN_1778059 CASP4 Caspase 4, apoptosis-related cysteine peptidase 1.21 4.30E-02
ILMN_2226015 LRRK2 Leucine-rich repeat kinase 2 1.21 3.97E-02
ILMN_1729115 UBE2S Ubiquitin-conjugating enzyme E2S 1.21 3.42E-02
ILMN_2230862 GYG1 Glycogenin 1 1.21 1.06E-02
ILMN_2374340 PLAUR Plasminogen activator, urokinase receptor 1.21 4.33E-02
ILMN_1678766 DYNLT1 Dynein, light chain, Tctex-type 1 1.21 4.65E-02
ILMN_1756953 GBP6 Guanylate binding protein family, member 6 1.21 4.23E-02
ILMN_1792682 MCTP2 Multiple C2 domains, transmembrane 2 1.21 1.96E-02
ILMN_1707286 PLBD1 Phospholipase B domain containing 1 1.20 2.52E-02
ILMN_1736327 CDC42EP3 CDC42 effector protein (Rho GTPase binding) 3 1.20 2.54E-02
ILMN_1716704 NLRC5 NLR family, CARD domain containing 5 1.20 3.87E-03
ILMN_1806651 PARP8 Poly (ADP-ribose) polymerase family, member 8 1.20 2.83E-02
ILMN_2189037 WDR52 WD repeat domain 52 1.20 4.38E-02
ILMN_1691104 PGAM4 Phosphoglycerate mutase family member 4 1.20 1.23E-02
ILMN_1685824 B4GALT5 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase,
polypeptide 5
1.20 3.47E-02
ILMN_1745686 MFHAS1 Malignant fibrous histiocytoma amplified sequence 1 1.20 2.24E-03
ILMN_2320330 MAL Mal, T-cell differentiation protein 1.20 3.54E-02
ILMN_2074860 KRT4 Keratin 4 1.21 1.54E-02
ILMN_1795639 MGMT O-6-methylguanine-DNA methyltransferase 1.21 4.50E-03
ILMN_1713731 ALOX12 Arachidonate 12-lipoxygenase 1.21 3.71E-02
ILMN_1658624 UBXN6 UBX domain protein 6 1.21 4.99E-03
ILMN_1727183 ZNF763 Zinc finger protein 763 1.21 1.81E-02
ILMN_1772876 ZNF395 Zinc finger protein 395 1.21 4.67E-03
ILMN_1728107 GNG7 Guanine nucleotide binding protein (G protein), gamma 7 1.22 3.06E-03
ILMN_1658957 MGC13005 Hypothetical LOC84771 1.22 7.00E-03
ILMN_2402131 TAF15 TAF15 RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 68kDa
1.23 2.83E-02
ILMN_1662587 PNPLA7 Patatin-like phospholipase domain containing 7 1.23 1.48E-02
ILMN_1662451 FCER2 Fc fragment of IgE, low affinity II, receptor for (CD23) 1.23 1.95E-02
ILMN_1676042 Unknown Unknown 1.23 4.56E-02
ILMN_2337928 CXCR5 Chemokine (C-X-C motif) receptor 5 1.23 1.01E-02
ILMN_1753782 ZNF266 Zinc finger protein 266 1.23 1.24E-02
ILMN_2409384 SIGLEC7 Sialic acid binding Ig-like lectin 7 1.23 1.45E-02
ILMN_1762764 SH3BGRL2 SH3 domain binding glutamic acid-rich protein like 2 1.23 3.96E-02
ILMN_1666089 OLIG1 Oligodendrocyte transcription factor 1 1.24 3.21E-02
ILMN_2374352 DBNDD1 Dysbindin (dystrobrevin binding protein 1) domain
containing 1
1.24 2.44E-02
ILMN_1659075 HLA-DOA Major histocompatibility complex, class II, DO alpha 1.24 1.75E-02
ILMN_1773567 LAMA5 Laminin, alpha 5 1.24 4.66E-04
ILMN_2307025 RBM12 RNA binding motif protein 12 1.25 1.43E-02
ILMN_1735712 KRT1 Keratin 1 1.26 2.42E-02
ILMN_1657996 AK098012 Uncharacterized protein ENSP00000383353. 1.27 4.34E-03
ILMN_2143314 SPIB Spi-B transcription factor (Spi-1/PU.1 related) 1.28 2.23E-02
ILMN_1695812 KRT72 Keratin 72 1.29 6.15E-03
ILMN_1685122 COL9A2 Collagen, type IX, alpha 2 1.29 8.81E-04
ILMN_1743911 SLC25A39 Solute carrier family 25, member 39 1.30 6.34E-03
ILMN_1752755 VWF von Willebrand factor 1.31 5.65E-03
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BLOOD-BASED AUTISM BIOMARKERSdesigned or optimized for this purpose, the 48-
probe SVM classifier of ASD also performed
quite well in distinguishing LD and DD subjects
from CNT subjects and from each other, with
eight errors made among the total of 80 subjects
assigned to these categories.
The list of 48 probes comprising the optimal SVM
classifier of ASDs was most significantly enriched
with genes related to immune responses in general
(nine genes: APOBEC3F, APOBEC3G, FCGR1B,
FCGR1C, GBP1, GBP4, GBP5, GCH1, and TAP1;
six-fold enrichment compared with chance expec-
tation; Bonferroni-corrected p .014), and genes of
the hemoglobin complex (four genes: AHSP, HBD,
HBG1, andHBG2; 142-fold enrichment; Bonferroni-
corrected p  1.8E4) and genes with guanine- or
guanylate-binding affinity (three genes: GBP1,
GBP4, and GBP5; 140-fold enrichment; Bonferroni-
corrected p  3.7E3) in particular. Although no
known canonical pathways were disproportion-
ately represented among the 48 genes, some links
between the genes along various biological path-
ways were observed through Ingenuity Pathway
Analysis (see Figure S1, available online).
DISCUSSION
In this study, we identified a blood-based gene ex-
pression profile that reliably identified subjects with
TABLE 2 Continued
Probe IDa Gene Symbol
ILMN_1703326 GPR44 G protein-coupled rec
ILMN_1814397 EPB42 Erythrocyte membrane
ILMN_1678707 TAF15 TAF15 RNA polymera
associated factor, 6
ILMN_1763322 CCR3 Chemokine (C-C motif
ILMN_1804350 LOC644852 Hypothetical LOC644
ILMN_1792323 HDC Histidine decarboxyla
ILMN_1751814 BC032353 Homo sapiens cDNA
ILMN_1654875 CLC Charcot-Leyden crysta
ILMN_1796216 VASH1 Vasohibin 1
ILMN_1705605 BC032353 Homo sapiens cDNA
ILMN_1696512 ERAF Erythroid associated fa
ILMN_1815527 HBD Hemoglobin, delta
ILMN_1796678 HBG1 Hemoglobin, gamma
ILMN_2084825 HBG2 Hemoglobin, gamma
Note: aThe 48 probe IDs in boldface type are those that comprised the o
bRows are sorted by ascending fold change in the ASD discovery sample c
at the top and largest positive fold change at the bottom of the table.ASDs near the age of first clinical signs. In fact,
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nominally higher accuracy (albeit not statistically sig-
nificantly higher) in the test sample than in the train-
ing sample. More typically, a classifier will perform
best in the sample in which it was trained, and a
drop-off in performance will be encountered in sub-
sequent test sets. In the present case, the apparent
difference in classification accuracy may stem from
the fact that the accuracy in the training sample
actually represents the average of 10 smaller cross-
validation samples (each with just four to five case
subjects and four to five comparison subjects),
whereas the value in the test set is derived from
measurement in the full test sample without addi-
tional cross-validation. Alternatively, the spike in ac-
curacy may represent a random fluctuation, and
additional test samples may very well show a decre-
ment in accuracy,whichwould not be unexpected. In
either event, further analyses and outside replications
of the optimal gene expression–based classifier of
ASDs are needed.
This promising work, while far from being
definitive, gives further proof to the recently
emerging principle that peripheral blood is a
potentially useful source of biomarkers for disor-
ders of the brain and other inaccessible tissues.23
The optimal ASD classifier panel of 48 mRNA
biomarkers, which was derived to maximize dif-
ferences between ASD subjects and those in the
e Product
Log2 Fold
Changeb p
44 1.31 2.92E-02
ein band 4.2 1.32 3.25E-03
TATA box binding protein (TBP)- 1.32 3.94E-02
ptor 3 1.32 2.97E-02
1.33 2.42E-02
1.34 3.46E-02
366 fis, clone THYMU2007824. 1.35 2.06E-02
ein 1.37 2.10E-02
1.39 2.22E-04
366 fis, clone THYMU2007824. 1.39 4.81E-03
1.43 1.34E-02
1.51 8.33E-03
2.04 9.24E-03
2.07 7.00E-03
l support vector machine (SVM) classifier of ASD.
red with the CNT discovery sample, with the largest negative fold changeGen
eptor
prot
se II,
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FLJ36
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FLJ36
ctor
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ptima
ompatwo unaffected control groups (TD and TIE), might
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GLATT et al.ultimately have clinical utility in the context of
high-risk screening where a heightened risk of
autism is feared or expected (i.e., in multiply af-
fected families). However, this samemodel was not
necessarily expected to provide maximal classifica-
tion accuracy for distinguishing ASD subjects from
those with other developmental delays or disor-
ders, such as the LD and DD subjects in our
sample. Nevertheless, when we performed these
comparisons, the 48-probe model of ASDs still
retained a very high degree of classification accu-
racy. This model, in contrast, may ultimately have
utility (and could be further optimized) for a gen-
eral population screen for ASDs at an early age, or
in the form of a test for autism among childrenwho
show at least some early warning signs of develop-
mental delay, whether or not those warning signs
ultimately manifest as a diagnosable disorder (e.g.,
ASDs, DD, or LD) or not (e.g., TIE).
Since we first demonstrated in 2005 the poten-
tial utility of transcriptome profiling in periph-
eral blood cells as a source of biomarkers for
mental illnesses,24 we and others have sought to
identify those select biomarkers that also might
shed light on the pathophysiology underlying
such disorders.20,25 Further work will be needed
to establish whether these dysregulated biomark-
ers are truly indicative of the early developmen-
tal pathogenesis of autism in the brain, and if the
dysregulation of these genes is governed by one
or more expression quantitative trait loci; how-
ever, neither is a prerequisite of an effective
biomarker. Yet, one of the 48 biomarkers in our
optimized SVM (IFI16, which encodes interferon,
-inducible 16) was previously found to be dys-
regulated in post mortem temporal cortex of
subjects with autism.26 In turn, although some of
the identified biomarkers may highlight potential
pathophysiological processes, our work is no
replacement for studies using animal models,
human post mortem brain tissue, induced pluri-
potent stem cells, and neuroimaging studies of
children living with autism.
Our analyses of gene expression data at just
one early timepoint in the lives of actively devel-
oping children preclude us from determining
whether the identified biomarkers of ASDs are or
will be stable over time. A recent study of longi-
tudinal gene expression in healthy individuals,27
as well as earlier small-scale studies,28-31 found
remarkable temporal stability in the expression
of most genes within individuals, with only 1%
to 2% of genes showing significant variability
JOURN
942 www.jaacap.orgover periods on the order of 1 month or longer;
however, these studies have not routinely exam-
ined children, or individuals affected with neu-
rodevelopmental disorders such as ASDs. Thus,
the stability of the particular biomarker signa-
tures we identified remains an empirical ques-
tion to be answered in due course. Toward that
objective, we continue to track the subjects reported
on here, as well as ascertain new subjects in this
study, which will provide an invaluable source of
replication given that other similar sample re-
sources are not yet available elsewhere. As we are
tracking these subjects longitudinally, we can ob-
serve how these putative biomarker profiles
change over time as symptoms also change natu-
rally or in response to intensive behavioral treat-
ment. Further evaluation of LD and DD subjects
will also shed light on the unique biomarker signa-
tures of these important conditions. Perhaps most
importantly, the peripheral blood gene expression
data (and linked genetic polymorphism and struc-
tural and functional neuroimaging data) generated
in our sample of children with a broad range of
clinical symptoms both within and beyond the
autistic spectrum could be harnessed for the pur-
pose of “reverse engineering” a new nosology of
childhood neurodevelopmental disorders based on
clusters of biological homogeneity rather than clin-
ical symptoms that may reflect common endpoints
of diverse etiologies.
The putative ASD biomarkers found here were
initially identified using an ANCOVA that ac-
counted for the age differences in the groups, and
the marker set advancing to the stage of classifier-
construction was filtered for genes showing a sig-
nificant age effect. Thus, the age difference between
diagnostic groups is not expected to be a major
driver of classification accuracy. We recognize,
however, that in real-world applications, a child’s
age—in conjunction with a particular gene expres-
sion profile—may be critically important for mak-
ing an ASD diagnosis. Therefore, with the addi-
tion of more subjects in this study across a
range of ages, we continue working to refine
distinct ASD biomarker signatures for children
of different ages, and to incorporate age itself
(along with the expression levels of both age-
dependent and age-independent genes) as a factor
influencing the performance of the diagnostic clas-
sifier.
Much work remains to be done, but even at this
stage the currently characterized biomarkers, if
replicated, could be harnessed by efforts to expe-
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BLOOD-BASED AUTISM BIOMARKERSdite and standardize the process of primary and
differential diagnosis, which presently involves
considerable time, effort, and uncertainty. Bio-
markers such as these, if deployed in a clinical
testing environment, should allow for earlier
identification of affected individuals, in turn
hastening their receipt of effective (perhaps
personalized) treatment and improving prog-
noses.2 Furthermore, biomarkers could form
the basis for early intervention and prevention
efforts targeting at-risk infants and toddlers,
which might significantly improve clinical out-
comes for affected infants.32 The identified bio-
markers may, in turn, suggest “treatable targets”
for future waves of medicinal chemistry and drug
discovery research. Collectively, these advances
would translate into an enormous improvement in
global public health. &
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BLOOD-BASED AUTISM BIOMARKERSSUPPLEMENT 1
METHOD
mRNA Extraction, Stabilization, Isolation,
and Storage
Total mRNA was extracted, stabilized, isolated,
and stored from each blood sample in the same
manner as described in our prior work.1–3
Briefly, 5 mL from each blood sample was
passed over a LeukoLOCK filter, which was
flushed with phosphate-buffered saline solu-
tion (PBS) and then fully saturated with RNAl-
ater.4 Each LeukoLOCK filter, containing
bound, isolated, stabilized, and purified white
blood cells, was sealed and stored in a sterile
box at 20°C. Once all samples were collected,
LeukoLOCK filters were processed in a batch
by flushing the filter with TRI reagent to lyse
the cells and isolate mRNA. Eluted mRNA
samples were stored at 20°C until transferred
to Scripps Genomic Medicine for quality assur-
ance and microarray hybridization.
mRNA Quantitation and Quality Control
The concentration of mRNA in each sample was
quantified by the absorption of ultraviolet light at
260 nm. The quantity of mRNA in each sample
exceeded the minimally sufficient amount re-
quired for microarray hybridization. The purity
of each mRNA sample was estimated by the
260:280 nm absorbance ratio, with an acceptable
range designated a priori as 1.7-2.1.
Reverse Transcription, Microarray Hybridization,
and Scanning
These 339 samples were assayed in a batch on
Illumina WG-6 v3 arrays (Illumina, San Diego,
CA) according to the manufacturer’s Direct Hy-
bridization Gene Expression protocol, using 500
ng of total RNA from each sample. Briefly, each
500-ng sample was suspended in a volume of 11
L and then amplified using Ambion’s Illumina
JOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
VOLUME 51 NUMBER 9 SEPTEMBER 2012TotalPrep-96 RNA Amplification kit. Amplifica-
tion steps consisted of the following: reverse
transcription to synthesize first-strand cDNA;
second-strand cDNA synthesis; cDNA purifica-
tion; in vitro transcription to synthesize biotin-
labeled cRNA; and 5) cRNA purification. cRNA
was then normalized to a concentration of 150
ng/L (in 10-L volume) and run through the
Illumina Gene Expression assay which includes a
16- to 20-hour overnight incubation at 58°C and
subsequent scanning of the expression beadchip
on a Bead Array Reader.
Microarray Data Normalization
and Transformation
Partek Genomics Suite software, version 6.3
(Partek, St. Louis, MO), was used for all analytic
procedures performed on microarray scan data.
First, raw probe-intensity values were imported;
then corrections for background signal were ap-
plied using the robust multi-array average
(RMA) method.5 An additional correction was
ade for the GC content of each probe. Expres-
ion levels of each probe underwent log2 trans-
ormation to yield distributions of data that more
losely approximated normality. The set of 339
rrays was then standardized using quantile nor-
alization.
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